Literature DB >> 12002338

HMG-I/Y in human breast cancer cell lines.

Christine E Dolde1, Mita Mukherjee, Chung Cho, Linda M S Resar.   

Abstract

The HMG-I/Y gene encodes the HMG-I and -Y architectural, chromatin binding proteins originally identified based on their association with chromosomal DNA. HMG-I/Y proteins bind to AT-rich regions in chromosomal DNA and alter gene expression. Increased HMG-I/Y protein expression also correlates with neoplastic transformation. Previous work from our laboratory has shown that HMG-I/Y is a direct c-Myc target gene involved in neoplastic transformation in Burkitt's lymphoma. We also observed that HMG-I/Y proteins have several oncogenic properties. In this report, we show that HMG-I/Y proteins are increased in several human breast cancer cell lines compared to a human breast cell line derived from normal breast cells. Decreasing HMG-I/Y proteins using an antisense ribozyme approach inhibits transformation in human breast cancer cells, suggesting that HMG-I/Y is important for the transformed phenotype observed in these cells. In addition, increased expression of the HMG-I isoform in normal human breast cells leads to transformation. These results suggest that HMG-I/Y is an oncogene important in the pathogenesis of human breast cancer. Although additional studies with animal models are needed, the antisense experiments, which result in blocking transformation suggest that this approach may have therapeutic potential in patients with breast cancer characterized by increased HMG-I/Y expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12002338     DOI: 10.1023/a:1014444114804

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

Review 2.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

3.  Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Authors:  Dwella M Nelson; Biju Joseph; Joelle Hillion; Jodi Segal; Judith E Karp; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2011-07-05

4.  The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.

Authors:  Rebecca C Osthus; Baktiar Karim; Julia E Prescott; B Douglas Smith; Michael McDevitt; David L Huso; Chi V Dang
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

5.  Hitting the bull's eye: targeting HMGA1 in cancer stem cells.

Authors:  Breann L Yanagisawa; Linda M S Resar
Journal:  Expert Rev Anticancer Ther       Date:  2014-01       Impact factor: 4.512

Review 6.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

7.  Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Authors:  Judith E Karp; B Douglas Smith; Linda S Resar; Jacqueline M Greer; Amanda Blackford; Ming Zhao; Dwella Moton-Nelson; Katrina Alino; Mark J Levis; Steven D Gore; Biju Joseph; Hetty Carraway; Michael A McDevitt; Lorena Bagain; Karen Mackey; Janet Briel; L Austin Doyle; John J Wright; Michelle A Rudek
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

8.  Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice.

Authors:  Francescopaolo Di Cello; James Shin; Kirsten Harbom; Cory Brayton
Journal:  Biochem Biophys Res Commun       Date:  2013-03-29       Impact factor: 3.575

9.  Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.

Authors:  Joelle Hillion; Lisa J Wood; Mita Mukherjee; Raka Bhattacharya; Francescopaolo Di Cello; Jeanne Kowalski; Ossama Elbahloul; Jodi Segal; John Poirier; Charles M Rudin; Surajit Dhara; Amy Belton; Biju Joseph; Stanley Zucker; Linda M S Resar
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

10.  The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer.

Authors:  Bethany M Bush; Ashton T Brock; Jiayue A Deng; Ronald A Nelson; Takita Felder Sumter
Journal:  Cell Biochem Funct       Date:  2012-09-07       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.